- Zimbabwe initiated the rollout of lenacapavir (LEN), a new long-acting HIV prevention drug.
- The program aims to benefit 271,000 individuals over the next three years.
- Projections indicate the drug could prevent over 9,000 new HIV infections.
- The launch signifies a critical moment in U.S.-Zimbabwe cooperation on HIV efforts.
The introduction of lenacapavir represents a significant advancement in Zimbabwe’s fight against HIV. Developed by Gilead Sciences, the injectable drug requires administration only twice a year, aiming to enhance adherence, particularly among vulnerable populations such as young women, pregnant and breastfeeding mothers, and other at-risk groups. This innovative approach is expected to bolster the nation’s efforts to control the HIV epidemic, building on its impressive progress in exceeding UNAIDS 95-95-95 targets.
U.S. Deputy Chief of Mission, Phillip Nervig, highlighted that LEN is at the forefront of HIV prevention science, already in use in the United States, Zambia, and Eswatini. He emphasized that the drug’s impact goes beyond statistics, representing thousands of Zimbabwean lives that will be saved and protected from HIV, allowing them to pursue their aspirations. The United States continues to be Zimbabwe’s leading health-sector donor, contributing over US$1.9 billion to HIV and AIDS initiatives.
The U.S. is now aligning its support with the America First Global Health Strategy, focusing on sustainable and measurable results to foster self-reliance in recipient countries. Nervig expressed confidence that with increased leadership from the Government of Zimbabwe, an AIDS-free generation is an achievable goal. The broader implications include a strengthened public health infrastructure and a healthier, more productive populace.
Timeline
- **March 9, 2026:** Reports emerge detailing the launch of lenacapavir in Zimbabwe.
- **Last week (prior to March 9, 2026):** The national launch event for lenacapavir took place, as referenced by US Deputy Chief of Mission Phillip Nervig.
Key Players
- **Government of Zimbabwe:** Initiating the national rollout of lenacapavir.
- **United States (U.S. Deputy Chief of Mission Phillip Nervig):** Leading donor and partner in the HIV prevention effort.
- **Gilead Sciences:** U.S. pharmaceutical company that developed lenacapavir.
- **UNAIDS:** International body setting global targets for HIV response, which Zimbabwe has exceeded.
